Abstract
INTRODUCTION: High-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked to metabolic reprogramming and recurrences in other cancers. METHODS: Data from 306 patients with advanced-stage HGSOC treated between 2008 and 2015 were analyzed. PHGDH expression levels were determined using immunohistochemistry and categorized as "low" or "high." RESULTS: PHGDH-high was associated with higher FIGO stage and increased use of neoadjuvant chemotherapy. Patients with PHGDH-high tumors had significantly worse survival than PHDH-low, even after adjusting for confounding factors.
Original language | English |
---|---|
Pages (from-to) | e1231-e1234 |
Journal | Oncologist |
Volume | 29 |
Issue number | 9 |
Early online date | 26 Jun 2024 |
DOIs | |
Publication status | Published - 6 Sept 2024 |
Keywords
- carcinoma
- female
- humans
- ovarian epithelial/drug therapy
- ovarian neoplasms/pathology
- phosphoglycerate dehydrogenase/metabolism